In English | En español
Questions About Cancer? 1-800-4-CANCER

Cancell/Cantron/Protocel (PDQ®)

  • Last Modified: 02/03/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document


Cancell/Cantron/Protocel was developed in the 1950s by a chemist who called it Entelev and provided it free of charge to patients with terminal cancer.[1,2] In 1984, production was taken over by a second manufacturer who distributed the mixture free of charge under the trademarked name Cancell to individuals with cancer, AIDS, and other conditions.[1,2]

The two principal manufacturers of Cancell/Cantron/Protocel have offered somewhat different explanations for cancer development, but their theories about how the mixture works are quite similar. According to the original manufacturer, human cells can be normal, cancerous, or primitive.[1] Each of these cellular forms is distinguished by the degree of oxygen utilization in cellular metabolism. Normal cells use aerobic metabolism (glycolysis plus additional biochemical reactions that require oxygen) to produce the energy needed for growth and maintenance. Primitive cells only use glycolysis, which is a much less efficient way to produce energy. It was proposed that normal cells become cancerous when, in response to certain damaging conditions such as chronic energy stress (a demand for energy greater than the cell’s ability to produce it), they reach a critical point and begin to rely mainly on glycolysis to produce energy. According to this theory, cancerous cells still maintain many of the features of normal cells and cannot be recognized by the body as foreign. According to the original manufacturer, Cancell/Cantron/Protocel causes cancer cells to become completely primitive, i.e., their residual aerobic metabolism is inhibited and they produce energy solely by glycolysis. The resulting primitive cells are then seen by the body as foreign and destroyed. While the aerobic metabolism of normal cells is also inhibited by Cancell/Cantron/Protocel, they are too far removed from the critical point to become cancerous or completely primitive.[1]

The second manufacturer suggested that a bacterium called Progenitor cryptocides is involved in cancer development.[1] According to this theory, P. cryptocides becomes activated in individuals whose bodies are damaged by an improper diet. Once activated, this bacterium helps cause damaged normal cells to shift their energy production from aerobic metabolism to glycolysis. When the demand for energy exceeds the damaged normal cell’s ability to produce it, the cell mutates and becomes cancerous. Once again, Cancell/Cantron/Protocel forces cancerous cells into a completely primitive state where they self-digest and are replaced by normal cells. The waste material produced by this self-digestion process is discarded by the body in a variety of ways: in urine, stool, vaginal discharge, or perspiration; it may also be vomited or coughed up.[1]

The idea that cancer cells show increased levels of glycolysis compared with normal cells is widely accepted, but this change in metabolism is not believed to be a fundamental cause of cancer development.[3-5] In addition, there is no scientific evidence that Cancell/Cantron/Protocel or any of its components can cause cells to produce energy solely by glycolysis or is able to treat cancer effectively.[1,6] Furthermore, there is no evidence to date to support the existence of the bacterium P. cryptocides.[7]

  1. Questionable methods of cancer management: Cancell/Entelev. CA Cancer J Clin 43 (1): 57-62, 1993 Jan-Feb.  [PUBMED Abstract]

  2. Cancell Alternative Cancer Treatment. Cottonwood, Ariz: Winter Works, 2002. Available online. Last accessed January 31, 2014. 

  3. Mathupala SP, Rempel A, Pedersen PL: Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29 (4): 339-43, 1997.  [PUBMED Abstract]

  4. Dang CV, Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24 (2): 68-72, 1999.  [PUBMED Abstract]

  5. Dills WL Jr: Nutritional and physiological consequences of tumour glycolysis. Parasitology 107 (Suppl): S177-86, 1993.  [PUBMED Abstract]

  6. Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton & Company, 1998. 

  7. Unproven methods of cancer management. Livingston-Wheeler therapy. CA Cancer J Clin 41 (3): A7-12, 1991 May-Jun.  [PUBMED Abstract]